文献速递鼻科

评估美泊利单抗对重度慢性鼻窦炎伴鼻息肉患者的治疗反应

Evaluating treatment response to mepolizumab in patients with severe CRSwNP.
PubMed 文献 · Rhinology · 2023-01-01

SYNAPSE研究的事后分析评估了美泊利单抗治疗重度慢性鼻窦炎伴鼻息肉(CRSwNP)的反应。在24周和52周未接受手术的患者中,美泊利单抗组达到各项反应标准的比例高于安慰剂组;24周未手术的美泊利单抗治疗患者中109例(55%)在≥3项标准上应答,52周增至126例(67%)。

要点

  • 24周未手术的美泊利单抗组109例(55%)在≥3项标准应答,52周增至126例(67%)。
  • 美泊利单抗组在24周和52周未手术患者中达到各项反应标准的比例均高于安慰剂组。
  • 美泊利单抗治疗的全应答者(5/5类)与非应答者(0/5类)基线特征无重大差异。

核心结论

  • 完成SYNAPSE研究的大多数患者既不需要手术也不需要系统性糖皮质激素,并且对美泊利单抗实现了渐进且持续临床应答,凸显美泊利单抗在重度CRSwNP中的治疗获益。

研究设计与样本

  • SYNAPSE(NCT03085797)是一项随机双盲研究,纳入接受标准治疗(SoC)仍适合重复手术的复发性、难治性重度CRSwNP患者。
  • 患者每4周皮下注射美泊利单抗100 mg或安慰剂,联合SoC治疗52周;本分析为事后分析,进一步描述治疗反应及其与患者特征的关系。
  • 在意向治疗人群407例中,至第24周和第52周分别有381例和343例未接受鼻窦手术。

主要发现

  • 至第24周和第52周未手术的患者中,美泊利单抗组达到各项反应标准的患者数多于安慰剂组。
  • 至第24周未手术的美泊利单抗治疗患者中,109例(55%)在≥3项标准上应答,至第52周增至126例(67%)。
  • 至第24周和第52周既未手术也未使用系统性糖皮质激素(SCS)的患者中,观察到相似的反应趋势。
  • 在两个时间点,美泊利单抗治疗的全应答者(5/5类)与非应答者(0/5类)基线特征无重大差异。

关键数值与推荐

  • 五项反应标准分别指示疾病特异性生活质量、鼻息肉大小、鼻塞、嗅觉丧失和总体症状的改善,于第24周和第52周评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SYNAPSE study (NCT03085797) demonstrated that mepolizumab decreased nasal polyp (NP) size and nasal obstruction in patients with chronic rhinosinusitis with NP (CRSwNP). METHODS: SYNAPSE, a randomized, double-blind study, included patients with recurrent, refractory, severe CRSwNP, eligible for repeated surgery despite receiving standard of care (SoC). Patients received 4-weekly mepolizumab 100 mg or placebo subcutaneously plus SoC for 52 weeks. This post hoc analysis further characterized treatment responses and association with patient characteristics. The proportion of patients meeting any and each of five response criteria indicating improvement in disease-specific quality of life, NP size, nasal obstruction, loss of smell, and overall symptoms at Weeks 24 and 52, were assessed in subgroups: 1) no surgery; 2) neither surgery nor systemic corticosteroids (SCS). RESULTS: Of 407 patients in the intention-to-treat population, 381 and 343 patients had no sinus surgery by Weeks 24 and 52, respectively. More mepolizumab- versus placebo-treated patients without surgery by Weeks 24 and 52 met each response criteria. Of the mepolizumab-treated patients without surgery by Week 24, 109 (55%) responded across >=3 criteria, increasing to 126 (67%) by Week 52. Similar response trends were seen for patients with neither surgery nor SCS by Weeks 24 and 52. At either timepoint, there were no major differences in baseline characteristics between mepolizumab-treated full- (5/5 categories) and non-responders (0/5 categories). CONCLUSIONS: Most patients who completed SYNAPSE required neither surgery nor SCS use and in addition achieved a progressive and sustained clinical response to mepolizumab underscoring the therapeutic benefits of mepolizumab in severe CRSwNP.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Hopkins C, Han JK, Lund VJ, et al. Evaluating treatment response to mepolizumab in patients with severe CRSwNP. Rhinology. 2023. PMID: 36716382. doi:10.4193/Rhin22.200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。